摘要
支气管哮喘(简称哮喘)是一种由多种免疫细胞介导的慢性气道炎症性疾病,其中2型哮喘是主要的哮喘表型。传统的哮喘治疗药物包括糖皮质激素、β2受体激动剂、白三烯受体拮抗剂等,但部分重度哮喘患者使用这些药物的疗效不佳或因不良反应而无法长期使用。近年来,针对2型炎性反应的靶向药物的研究与开发获得巨大成功。本文就用于哮喘治疗的靶向药物的研究进展作一概要介绍。
Bronchial asthma(asthma)is a chronic inflammatory airway disease mediated by various immune cells,of which type 2 asthma is the main phenotype of asthma.The traditional drugs for asthma include glucocorticoids,β2 receptor agonists,leukotriene receptor antagonists and so on.However,some patients with severe asthma do not respond well to these drugs or cannot use them for a long time due to adverse effects.The research and development of the targeted drugs for type 2 inflammation has achieved great success in recent years.This review aimed to briefly introduce the research progress of targeted drugs for the treatment of asthma.
作者
史婧
金美玲
SHI Jing;JIN Meiling(Department of Allergy,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《上海医药》
CAS
2023年第19期20-26,共7页
Shanghai Medical & Pharmaceutical Journal
